Itovebi, Ibrance, and Faslodex significantly improved OS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer compared to placebo. The INAVO120 trial showed a median OS of 34.0 months ...
In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.
The evERA study showed significant PFS improvements with giredestrant plus everolimus in ER-positive, HER2-negative breast ...
The FDA has approved the combination of lurbinectedin (Zepzelca) and atezolizumab (Tecentriq) as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) ...
The U.S. Food and Drug Administration (FDA) has granted priority review and breakthrough therapy designation to the ...
MedPage Today on MSN
More Evidence for Lower Ribociclib Dose in Advanced Breast Cancer
Patients receiving ribociclib 400 mg had a shorter QTcF (12.5 vs 19.7 ms at cycle 1 day 15, 2 hours post-dose) and a lower ...
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy The ...
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with ...
Already a blockbuster therapy for advanced breast cancer and other indications like gastric cancer, Enhertu made revenues of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback